S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
NASDAQ:IMGN

ImmunoGen (IMGN) Stock Forecast, Price & News

$15.37
+1.00 (+6.96%)
(As of 06/5/2023 ET)
Compare
Today's Range
$14.81
$15.59
50-Day Range
$3.69
$15.37
52-Week Range
$3.10
$15.59
Volume
10.21 million shs
Average Volume
5.46 million shs
Market Capitalization
$3.47 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.71

ImmunoGen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
10.8% Downside
$13.71 Price Target
Short Interest
Healthy
6.89% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.53
Upright™ Environmental Score
News Sentiment
0.19mentions of ImmunoGen in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.55) to ($0.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

642nd out of 986 stocks

Pharmaceutical Preparations Industry

307th out of 478 stocks


IMGN stock logo

About ImmunoGen (NASDAQ:IMGN) Stock

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.

Receive IMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter.

IMGN Stock News Headlines

MarketBeat Week in Review – 5/8 - 5/12 (IMGN)
Inflation, bank woes, interest rates, and the debt ceiling led to more of the new normal for equity markets. Here are some of this week's most popular articles
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results
Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug
How A.I. Could Make Most 21st Century Diseases EXTINCT
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Piper Sandler Reaffirms Their Buy Rating on ImmunoGen (IMGN)
ImmunoGen (NASDAQ:IMGN) Sets New 12-Month High at $15.45
ImmunoGen (NASDAQ: IMGN)
When Will ImmunoGen, Inc. (NASDAQ:IMGN) Breakeven?
ImmunoGen Sees Unusually High Options Volume (NASDAQ:IMGN)
ImmunoGen: Making A Successful Comeback
See More Headlines

IMGN Price History

IMGN Company Calendar

Last Earnings
4/28/2023
Today
6/05/2023
Next Earnings (Estimated)
8/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IMGN
CUSIP
45253H10
Employees
106
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$13.71
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
-10.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-222,930,000.00
Net Margins
-198.88%
Pretax Margin
-197.87%

Debt

Sales & Book Value

Annual Sales
$108.78 million
Book Value
$0.71 per share

Miscellaneous

Free Float
214,608,000
Market Cap
$3.47 billion
Optionable
Optionable
Beta
0.89

Social Links


Key Executives

  • Mark Joseph EnyedyMark Joseph Enyedy
    President, Chief Executive Officer & Director
  • Renee Lentini
    VP-Finance, Chief Financial & Accounting Officer
  • Anna Berkenblit
    Chief Medical Officer & Senior Vice President
  • Michael J. Vasconcelles
    EVP-Research, Development & Medical Affairs
  • Robert Herbst
    Vice President-Technical Operations













IMGN Stock - Frequently Asked Questions

Should I buy or sell ImmunoGen stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMGN shares.
View IMGN analyst ratings
or view top-rated stocks.

What is ImmunoGen's stock price forecast for 2023?

5 equities research analysts have issued 12 month price targets for ImmunoGen's stock. Their IMGN share price forecasts range from $9.00 to $22.00. On average, they expect the company's stock price to reach $13.71 in the next year. This suggests that the stock has a possible downside of 10.7%.
View analysts price targets for IMGN
or view top-rated stocks among Wall Street analysts.

How have IMGN shares performed in 2023?

ImmunoGen's stock was trading at $4.96 at the start of the year. Since then, IMGN stock has increased by 209.7% and is now trading at $15.36.
View the best growth stocks for 2023 here
.

Are investors shorting ImmunoGen?

ImmunoGen saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 15,580,000 shares, a decrease of 32.6% from the April 30th total of 23,100,000 shares. Based on an average trading volume of 6,540,000 shares, the short-interest ratio is currently 2.4 days.
View ImmunoGen's Short Interest
.

When is ImmunoGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our IMGN earnings forecast
.

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) posted its quarterly earnings results on Friday, April, 28th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.09. The biotechnology company had revenue of $49.90 million for the quarter, compared to the consensus estimate of $21.63 million. ImmunoGen had a negative trailing twelve-month return on equity of 135.94% and a negative net margin of 198.88%. The firm's quarterly revenue was up 31.0% compared to the same quarter last year. During the same period last year, the company posted ($0.10) EPS.

What guidance has ImmunoGen issued on next quarter's earnings?

ImmunoGen issued an update on its FY 2023 earnings guidance on Friday, April, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $45.00 million-$50.00 million, compared to the consensus revenue estimate of $108.34 million.

What is Mark J. Enyedy's approval rating as ImmunoGen's CEO?

16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees.

What other stocks do shareholders of ImmunoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX).

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

Who are ImmunoGen's major shareholders?

ImmunoGen's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.96%), State Street Corp (7.55%), Wellington Management Group LLP (4.36%), Maverick Capital Ltd. (3.48%), Geode Capital Management LLC (1.79%) and Artisan Partners Limited Partnership (1.41%).
View institutional ownership trends
.

How do I buy shares of ImmunoGen?

Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunoGen's stock price today?

One share of IMGN stock can currently be purchased for approximately $15.36.

How much money does ImmunoGen make?

ImmunoGen (NASDAQ:IMGN) has a market capitalization of $3.47 billion and generates $108.78 million in revenue each year. The biotechnology company earns $-222,930,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis.

How many employees does ImmunoGen have?

The company employs 106 workers across the globe.

Does ImmunoGen have any subsidiaries?
The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..
Read More
How can I contact ImmunoGen?

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The official website for the company is www.immunogen.com. The biotechnology company can be reached via phone at (781) 895-0600, via email at courtney.okonek@immunogen.com, or via fax at 781-895-0611.

This page (NASDAQ:IMGN) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -